HydRegen Secure BBSRC, EPSRC and IUK Grant Funding to Unlock Sustainable Biocatalytic Hydrogenation

HydRegen, the biotechnology company enabling sustainable chemical manufacturing, and researchers from the University of Nottingham’s Faculty of Engineering collaborate in a project to unlock sustainable biocatalytic hydrogenation and receive grant funding from BBSRC, EPSRC and IUK to complete the feasibility study.

The joint investment by the Biotechnology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council (EPSRC) and Innovate UK will enable HydRegen to tackle the challenges in manufacturing readiness of its technologies, by intensifying and scaling enzyme production with a focus on applying it to a demonstrator process for quinuclidinol production. Quinuclidinol is an important chemical building-block that is used in the production of many important drugs and other end-products and has a variety of uses in organic synthesis. As such, it is an excellent exemplar for novel sustainable manufacturing technology.

The project between HydRegen and the University of Nottingham focused on intensification of metallo-enzyme production to unlock sustainable biocatalytic hydrogenation aims to lower the cost of production for three enzymes that are critical to HydRegen’s production of the chemical building-block quninuclidinol. By validating the cost and sustainability metrics for quinuclidinol manufacture they can produce a ‘license-ready' bio-based manufacturing route for quinuclidinol that meets the needs for reshoring key API production.

The BBSRC, EPSRC and Innovate UK are supporting 34 feasibility studies across the UK to develop and improve sustainable biomanufacturing. The programme aims to enhance UK global competitiveness by supporting research and innovation that focuses on developing new and disruptive sustainable biomanufacturing products and processes that will support UK biomanufacturing in becoming net zero and resource efficient, resilient and responsive, technologically advanced and digital by 2050.

We are excited to embark on this exciting project with Dr Simone Morra, and his team, at the University of Nottingham. His expertise in novel hydrogen cycling enzymes and cutting-edge knowledge will be a great asset in helping us to increase the manufacturing readiness for 3 of HydRegen’s critical metallo-enzymes and builds out our in-house R&D capabilities. This has the potential to make a step-change in HydRegen’s ability to lower cost and increase scalability of hydrogenase production.”

Dr Rhiannon Evans, Head of Enzyme production and Molecular Biology, HydRegen

Dr Simone Morra, Assistant Professor at the University of Nottingham comments: “I started collaborating with HydRegen back in 2022 via a via BBSRC-NIBB funded project and I’m excited to continue working with them on this new project. My team and I have a deep expertise in novel hydrogenase enzymes that are able to cycle H2 and H+. These are the enzymes of interest to HydRegen due to their unusual balance in ease of production and ease of handling. We have the know-how and facilities in enzyme production spanning early-stage academic research through to evaluation of scalable enzyme production in bioreactors to transfer to HydRegen as part of this collaboration for process intensification and scale up of metallo-enzyme production.”

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Surface Plasmon Resonance Sensors: Transforming Drug Development and Clinical Diagnostics